Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles

Anti-Cancer Drugs

Volumn 23, Issue 2, 2012, Pages 185-190

  Guo, Xinhong ^a,b   Xing, Yabing ^a   Mei, Qian ^a   Zhang, Hongling ^a   Zhang, Zhenzhong ^a   Cui, Fude ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

2 methoxyestradiol; cellular uptake; cytotoxicity; MCF 7; PC 3; SK N SH; SLN

Indexed keywords

2 METHOXYESTRADIOL; GLYCEROL STEARATE; SOLID LIPID NANOPARTICLE; SULFORHODAMINE B; SURFACTANT;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RELEASE; DRUG SYNTHESIS; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; ESTRADIOL; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; SONICATION; SURFACE PROPERTIES;

EID: 84855236495     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834cf8d0     Document Type: Article

References (23)

1. Dobos J, Timar J, Bocsi J, Burian Z, Nagy K, Barna G, et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 2004; 112:771-776. (Pubitemid 39435261)
2. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents. Br J Cancer 2004; 90:932-937. (Pubitemid 38406609)
3. Dingli D, Timm M, Russell SJ,Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 2002; 8:3948-3954. (Pubitemid 35424790)
4. Huh JI, Calvo A, Charles R, Green JE. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1expression. Cancer Res 2006; 66:3495-3503.
5. Dahut WL, Lakhani N, Gulley JL, Arlen PM, Kohn EC, Kotz H, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and antiapoptotic agent in patients with solid tumors. Cancer Biol Ther 2006; 5:22-27. (Pubitemid 43234973)
6. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2006; 25:41-48.
7. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, et al. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: Role of tumor necrosis factor-alphastimulated gene6. Clin Cancer Res 2006; 12:980-988. (Pubitemid 43259881)
8. Guo XH, Cui FD, Xing YB, Mei Q, Zhang ZZ. Investigation of a new injectable thermosensitive hydrogels loading solid lipid nanoparticles. Pharmazie 2011;65:1-5.
9. Anita L, Piyun C, Peidi H, Stein S, Sinko PJ. Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. J Control Release 2006; 112:333-342. (Pubitemid 43737145)
10. Qiao MX, Chen DW, Ma XC, Liu YJ. Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: Synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm 2005; 294:103-112.
11. Si-Shen F, Gang R, Qiu-Tian L. Fabrication and characterizations of a novel drug delivery device liposomes-in-microsphere (LIM). Biomaterials 2004; 25:5181-5189.
12. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878-884. (Pubitemid 34742121)
13. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6:583-592. (Pubitemid 44140857)
14. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28:2137-2146.
15. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673-680. (Pubitemid 39297116)
16. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancercells. Int J Pharm 2008; 361:239-244.
17. Lu B, Xiong SB, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006; 28:86-95.
18. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A 549 cancer cells. Int J Pharm 2008; 348:137-145. (Pubitemid 350266242)
19. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000; 210:61-67. (Pubitemid 32332642)
20. Dong YC, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26:6068-6076.
21. Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. Int J Pharm 2008; 359:104-110.
22. Lv QZ, Yu AH, Xi YW, Li HL, Song ZM, Cui J, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm 2009; 372:191-198.
23. Shiokawa T, Hattori Y, Kawano K, Ohguchi Y, Kawakami H, Toma K, et al. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res 2005; 11: 2018-2025. (Pubitemid 40471868)